Expanding roles in myeloma: Kraeber-Bodéré and colleagues review new developments in multiple myeloma treatment, including prognostic evaluation and response assessment, with an emphasis on nuclear medicine techniques.
Page 1331
Auger electron–emitting therapy potential: Bolcaen and colleagues summarize expert perspectives on the current status of Auger electron radiopharmaceutical therapy, identify hurdles to development, and make recommendations for future research.
Page 1344
Future of U.S. nuclear medicine: Graham offers perspective on the implications of nuclear medicine workforce shortages and outlines recommendations for meeting the challenges of training physicians in this rapidly evolving discipline.
Page 1352
ABNM looks at nuclear medicine future: Segall and colleagues provide data from the American Board of Nuclear Medicine on declining numbers of nuclear medicine residents in training and the effects of new pathways to certification, including dual training programs.
Page 1354
Stronger together: Grady and colleagues look at the multidisciplinary history of radiopharmaceutical imaging and therapy and emphasize the importance of inclusivity in nuclear medicine training to encompass collaboration and cooperation across existing boundaries.
Page 1356
Redefining nuclear medicine for the future: Czernin and Calais call for new standards with integrated programmatic and financial independence to strengthen future nuclear medicine training with breakthrough technologies that attract young talent.
Page 1359
Toward integrated independence: Johannes Czernin discusses the future of radiolabeled theranostics and associated training and practice with subject-matter leaders Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber.
Page 1361
ABY-025 PET in HER2 breast cancer: Alhuseinalkhudhur and colleagues investigate uptake of this 68Ga-labeled human epidermal growth factor receptor 2–binding PET tracer in biopsy results and early treatment response in primary and metastatic breast cancer.
Page 1364
[18F]FDG PET/CT in sarcoma: Metser and colleagues determine the impact of [18F]FDG PET/CT on initial staging, restaging, clinical management, and outcomes of patients with soft-tissue and bone sarcomas and negative/equivocal findings for metastases or limited recurrence on conventional work-up.
Page 1371
Targeting CD206 in humans: Gondry and colleagues evaluate the safety, biodistribution, dosimetry, and tumor uptake of a [68Ga]Ga-NOTA-anti-CD206 single-domain antibody tracer targeting antiinflammatory macrophages in patients with solid tumors.
Page 1378
68Ga-FAPI PET/CT and ECD: Ma and colleagues explore the ability of 68Ga–fibroblast activation protein inhibitor PET/CT to detect and differentiate lesions in patients with Erdheim–Chester disease.
Page 1385
Pain outcomes and 223Ra therapy: Palmedo and colleagues detail the results of a study of pain- and bone pain–related quality of life in patients with metastatic castration-resistant prostate cancer and symptomatic bone metastases receiving 223Ra.
Page 1392
68Ga-FAPI and 18F-FDG PET/CT in lymphoma: Chen and colleagues compare the diagnostic performance of 68Ga-labeled fibroblast activation protein inhibitor and 18F-FDG PET/CT in diagnosing lymphomas and characterize the influence of associated markers on tracer uptake by involved lesions.
Page 1399
SSTR antagonist PET/CT in NETs: Lin and colleagues contrast the performances of 68Ga-DOTATATE and 68Ga-NODAGA-JR11, a novel somatostatin receptor antagonist, in whole-body PET imaging of patients with metastatic, well-differentiated neuroendocrine tumors.
Page 1406
Hypocalcemia in 177Lu-PSMA responders: Kumar and colleagues present case reviews of 2 men with marked hypocalcemic osteosclerotic responses to 177Lu-PSMA-I&T therapy, with additional data estimating the general clinical incidence of such responses.
Page 1412
Appropriate use of 177Lu-PSMA-617 RLT: Hope and colleagues provide an SNMMI expert consensus document with standardized guidance for selection and management of patients for 177Lu-PSMA radioligand therapy.
Page 1417
CXCR4-directed endoradiotherapy of DSRCT: Hartlapp and colleagues report on experience with the clinical potential of C-X-C motif chemokine receptor 4–directed imaging and endoradiotherapy in desmoplastic small round cell tumors, a rare sarcoma subtype.
Page 1424
177Lu-PSMA kinetic assessment: Straub and colleagues use posttherapy SPECT/CT to test the hypothesis that 177Lu-PSMA-617 tracer kinetics within tumors may influence treatment effectiveness in metastasized castration-resistant prostate cancer.
Page 1431
225Ac-PRIT for peritoneal carcinomatosis: Chung and colleagues investigate the use of human epidermal growth factor receptor 2 225Ac-pretargeted radioimmunotherapy to treat a mouse model of human epithelial ovarian carcinoma SKOV3 xenografts growing as peritoneal carcinomatosis.
Page 1439
225Ac PRIT in ovarian cancer: Li and colleagues provide context and commentary on preclinical research published in this issue of JNM on a promising pretargeted radioimmunotherapeutic approach for treating HER2-expressing ovarian peritoneal carcinomatosis.
Page 1446
FAPI tetramers in cancer theranostics: Pang and colleagues evaluate the tumor-targeting characteristics of radiolabeled fibroblast activation protein inhibitor multimers in vitro and in vivo, with implications for design of new FAP-targeted agents based on the polyvalency principle.
Page 1449
Red marrow uptake of [177Lu]Lu-DOTATATE: Hemmingsson and colleagues use SPECT/CT after the first [177Lu]Lu-DOTATATE treatment cycle in neuroendocrine neoplasms to identify and quantify specific red marrow uptake.
Page 1456
Data-driven STP dosimetry: Wang and colleagues detail patient data–driven regression models to reduce sensitivity to time-point selection in dosimetry-guided radiopharmaceutical therapy and compare these new models with commonly used single-time-point methods.
Page 1463
MC 90Y vial activity assessments: Auditore and colleagues use Monte Carlo simulations to investigate the causes of observed discrepancies between PET/CT-measured and vendor-calibrated activities for 90Y glass and resin microspheres.
Page 1471
Coronary 18F-fluoride uptake: Daghem and colleagues characterize the natural history of coronary 18F-fluoride uptake over 12 mo in patients with advanced chronic coronary artery disease or recent myocardial infarction.
Page 1478
18F-NaF PET in murine CAVD: Ahmad and colleagues explore the utility of 18F-NaF PET/CT for tracking murine aortic valve calcification and examine development of calcification with aging and its interdependence with bicuspid aortic valve and aortic stenosis.
Page 1487
[18F]SNFT-1 for tau PET imaging: Harada and colleagues elucidate the binding properties of this novel tracer with high sensitivity and specificity to tau pathology in Alzheimer disease and compare it with other reported 18F-labeled tau tracers.
Page 1495
PSMA-negative lesion progression: Murthy and colleagues present a case study of a patient with metastatic castration-resistant prostate cancer treated with 5 cycles of 177Lu-PSMA radioligand therapy.
Page 1502
- © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.